Document is current

Article History

Received: 5 August 2021

Accepted: 21 August 2021

First Online: 3 September 2021

Declarations

:

: The ethical committees of the participating institutions approved the study protocol. Written, informed consent for participation in the study was obtained from all the subjects. This trial was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.

: All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language. If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.

: AT received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline. TI received honoraria from the Organization for Clinical Medicine Promotion. TO received honoraria from Ono Pharmaceutical, Otsuka Pharmaceutical, Novartis Pharma, and Astrazeneca, and research grants outside the submitted work from Ono Pharmaceutical, Amgen Astellas BioPharma, Pfizer Japan, Alnylam Pharmaceuticals, and Alexion. AK received honoraria from Sumitomo Dainippon Pharma, Daiichi-Sankyo, Ono Pharmaceutical, AstraZeneca, and Takeda. YS received honoraria from Mitsubishi Tanabe. KN received research grants from Asahi Kasei, Astellas, Bayer, Boehringer Ingelheim, Mitsubishi Tanabe, Teijin, and Terumo, scholarships from Astellas, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Daiichi Sankyo Healthcare, Takeda, and Teijin, and personal fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo Healthcare, Eli Lilly, Kowa, Mitsubishi Tanabe, MSD, Novartis, Ono, Takeda, and Teijin. All other authors declare no competing interests.